Going to ESC Congress 2017? For the latest in research and clinical advances, be sure to attend the many debates, lectures and poster presentations by Brigham and Women’s Hospital cardiovascular specialists in Barcelona, August 26th to August 30th, 2017.

Notable BWH Presentations

Sunday, August 27th

- 11:00AM-12:30PM
  **Dr. Peter Libby**
  Lipids in Atherosclerosis – Evolving Concepts Co-Chair
  Location: Dublin – Village 1

- 11:15AM
  **Dr. Marc Sabatine**
  Do we need PCSK9 inhibitors in post-MI patients?
  Location: Dali – The Hub

- 11:55AM
  **Dr. Marc Sabatine**
  Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO
  Location: Dali – The Hub

- 12:04PM
  **Dr. Eugene Braunwald**
  Discussant review: Cardiovascular Outcomes for People using Anticoagulation Strategies (COMPASS) trial: Primary Results
  Hot Line: Late-Breaking Clinical Trials 1
  Location: Barcelona – Main Auditorium
12:50PM
Dr. Marc Sabatine
CVD prevention and event reduction
PCSK9 inhibitors: the next chapter in cardiovascular disease prevention
Location: Barcelona – Main Auditorium

1:15PM
Dr. Robert Giugliano
Translating ENGAGE AF-TIMI 48 into clinical practice
DS Satellite Symposium, “The changing landscape of oral anticoagulation for atrial fibrillation”
Location: Oslo – Village 7

2:00-2:22PM
Dr. Peter Libby
The Role of Inflammation in Vascular Disease
Innate Immunity and Acute Coronary Syndromes
Location: Dublin – Village 1

2:00-3:30PM
Dr. Mandeep Mehra
Advanced heart failure: when drugs alone are not enough - Selection criteria for transplantation and destination therapy
Location: Lisbon – Village 9

2:10-2:30PM
Dr. Robert Giugliano
Press Conference - Clinical Trial Update 1
Clinical efficacy and safety of achieving very low LDL-C levels with the PCSK9 inhibitor Evolocumab in the FOURIER outcomes trial
Location: TBA

3:07PM
Dr. Eugene Braunwald
Sharing of Clinical trial data
Developments in cardiovascular translational research
Location: Goya – The Hub

4:30PM
Dr. Marc Sabatine
CSK9 inhibitors and cardiovascular outcomes – Represented in New England Journal of Medicine by the FOURIER and SPIRE trials
Highlights from the New England Journal of Medicine: editors’ choice
Location: Dali – The Hub
Monday, August 28th

- **8:30AM-12:30PM**
  - **Dr. Arman Qamar**
    Thrombosis & Atrial Fibrillation
    Efficacy & Safety of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation & Hepatic Disease: Insights from the ENGAGE AF-TIMI 48 Trial
    Location: Posters – Poster Area

- **8:30AM**
  - **Dr. Tze-Fan Chao**
    The usefulness of the TIMI-AF score in the prediction of ischemic stroke and bleeding for Asian patients with atrial fibrillation
    Location: Posters – Poster Area

- **8:48AM**
  - **Dr. Marc Bonaca**
    Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54
    Antithrombotic strategies in coronary artery disease
    Location: Agora 1 – Agora

- **9:37-10:00AM**
  - **Dr. Laura Mauri**
    Starting, stopping, and everything in between: recent data concerning dual antiplatelet therapy in ACS
    How long is long enough? When to stop DAPT after an acute coronary syndrome?
    Location: Bucharest – Village 8

- **9:37AM**
  - **Dr. Marc Pfeffer**
    Heart Failure Patients Tend to Have More Than One Problem: how to manage co-morbidities
    Kidney dysfunction in heart failure: why worry?
    Location: Lisbon Village – 9

- **12:07PM**
  - **Dr. Marc Pfeffer**
    Heart failure with preserved ejection fraction - A clinical dilemma
    Treatment of HFpEF: drugs and devices on the horizon
    Location: Warsaw Village – 9
12:50-12:55PM

Dr. Peter Libby
ATHEROSCLEROSIS AND SECONDARY CARDIOVASCULAR DISEASE PREVENTION: INFLAMMATION AND LDL-CHOLESTEROL
Atherosclerosis and the cardiovascular continuum CO-CHAIR & Speaker
Location: Bucharest – Village 8

1:05PM

Dr. Marc Pfeffer
GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: A new treatment paradigm?
Translating trials into practice – Clinical implications
Location: Miro – The Hub

1:25PM

Dr. Christian Ruff
How can we appropriately treat multimorbid patients with AF?
Protecting patients through responsible use of novel oral anticoagulants (NOACs) ... The right dose for the right patient for stroke prevention
Location: Chisinau – Village 4

2:22-2:45PM

Dr. Peter Libby
MAKING AN IMPACT: OPTIMAL SECONDARY PREVENTION FOLLOWING ACUTE CORONARY SYNDROMES
Targeting inflammation in patients after an acute coronary syndrome
Location: Bucharest – Village 8

2:30PM

Dr. Robert Giugliano
Clinical Trial Update 1
Clinical efficacy and safety of achieving very low LDL-C levels with the PCSK9 inhibitor Evolocumab in the FOURIER outcomes trial
Location: Dali – The Hub

3:07PM

Dr. Eugene Braunwald
Drug therapy of heart failure: what is next?
Options and challenges for drug therapy of heart failure
Location: Warsaw – Village 9
3:45-4:10PM  
Dr. Christian Ruff  
Opening remarks – Addressing the needs of the multi-morbid patients with AF  
Location: Gaudi – The Hub

3:45-4:15PM  
Dr. Peter Libby  
ATHEROSCLEROSIS, CARDIOVASCULAR RISK FACTORS AND SECONDARY PREVENTION: ARE WE MAKING PROGRESS?  
Location: Miro – The Hub

Tuesday, August 29th

8:30AM  
Dr. Martin Landray  
Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized Evaluation of the effects of anacetrapib through lipid-modification  
Hot-Line: Late-Breaking Clinical Trials 4  
Location: Barcelona – Main Auditorium

8:30AM  
Dr. Eugene Braunwald  
Positioning of the topic – Why left main disease is different  
Left main is now a domain of interventional cardiology  
Location: Spotlight Stage

12:30PM  
Dr. Eugene Braunwald  
Aspirin for life – Chairperson conclusion  
Aspirin for life  
Location: Dali – The Hub

1:05PM  
Dr. Marc Bonaca  
Emerging science: recent evidence and science on the horizon  
State of the art lipid treatment in coronary patients in 2017  
Location: Beirut – Village 3

2:00-3:30PM  
Dr. Mandeep Mehra  
Innovative treatment strategies in advanced heart failure  
State of the Art: advanced heart failure - The rise of machines  
Location: Warsaw – Village 9
4:48PM  
**Dr. Gregory Piazza**  
Interventions in the pulmonary circulation  
Echocardiographic improvement after short-duration, low-dose tPA regimens for ultrasound-facilitated, catheter-based fibrinolysis in submassive PE: OPTALYSE-PE  
Location: Rabat – Village 7

4:54PM  
**Dr. Jaris DeGroot**  
Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A subanalysis of the ENGAGE AF – TIMI 48 study  
Anticoagulation in atrial fibrillation  
Location: Agora 2 – Agora